Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate NervGen Pharma Corp. before investing.
In this article, we go over a few key elements for understanding NervGen Pharma Corp.’s stock price such as:
- NervGen Pharma Corp.’s current stock price and volume
- Why NervGen Pharma Corp.’s stock price changed recently
- Upgrades and downgrades for NGEN from analysts
- NGEN’s stock price momentum as measured by its relative strength
About NervGen Pharma Corp. (NGEN)
Before we jump into NervGen Pharma Corp.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company’s lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer’s disease; and NVG-300, which is in a preclinical model of ischemic stroke and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.
Want to learn more about NervGen Pharma Corp.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about NervGen Pharma Corp..
NervGen Pharma Corp.’s Stock Price as of Market Close
As of April 15, 2026, 3:16 PM, CST, NervGen Pharma Corp.’s stock price was $4.290.
NervGen Pharma Corp. is up 2.39% from its previous closing price of $4.190.
During the last market session, NervGen Pharma Corp.’s stock traded between $4.160 and $4.350. Currently, there are approximately 53.61 million shares outstanding for NervGen Pharma Corp..
NervGen Pharma Corp.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.
NervGen Pharma Corp. Stock Price History
NervGen Pharma Corp.’s (NGEN) price is currently up 13.79% so far this month.
During the month of April, NervGen Pharma Corp.’s stock price has reached a high of $4.670 and a low of $3.775.
Over the last year, NervGen Pharma Corp. has hit prices as high as $6.300 and as low as $1.500. Year to date, NervGen Pharma Corp.’s stock is up 2144900%.
Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions
What Caused NervGen Pharma Corp. Stock’s Price to Rise?
Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?
One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of April 14, 2026,, no analysts have changed their rating of NervGen Pharma Corp.’s stock over the last month.
Additionally, you'll want to evaluate NervGen Pharma Corp.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on NervGen Pharma Corp.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.
Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.
Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about NervGen Pharma Corp. (NGEN) by visiting AAII Stock Evaluator.
Relative Price Strength of NervGen Pharma Corp.
Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.
For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.
As of April 14, 2026, NervGen Pharma Corp. has a weighted four-quarter relative price strength of 8.08%, which translates to a Momentum Score of 74 and is considered to be Strong.
Want to learn more about how NervGen Pharma Corp. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.
NervGen Pharma Corp. Stock Price: Bottom Line
As of April 15, 2026, NervGen Pharma Corp.’s stock price is $4.290, which is up 2.39% from its previous closing price.
AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like NervGen Pharma Corp. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.
Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.
Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate NervGen Pharma Corp. before investing.
In this article, we go over a few key elements for understanding NervGen Pharma Corp.’s stock price such as:
- NervGen Pharma Corp.’s current stock price and volume
- Why NervGen Pharma Corp.’s stock price changed recently
- Upgrades and downgrades for NGEN from analysts
- NGEN’s stock price momentum as measured by its relative strength
About NervGen Pharma Corp. (NGEN)
Before we jump into NervGen Pharma Corp.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company’s lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer’s disease; and NVG-300, which is in a preclinical model of ischemic stroke and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.
Want to learn more about NervGen Pharma Corp.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about NervGen Pharma Corp..
NervGen Pharma Corp.’s Stock Price as of Market Close
As of April 15, 2026, 3:16 PM, CST, NervGen Pharma Corp.’s stock price was $4.290.
NervGen Pharma Corp. is up 2.39% from its previous closing price of $4.190.
During the last market session, NervGen Pharma Corp.’s stock traded between $4.160 and $4.350. Currently, there are approximately 53.61 million shares outstanding for NervGen Pharma Corp..
NervGen Pharma Corp.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.
NervGen Pharma Corp. Stock Price History
NervGen Pharma Corp.’s (NGEN) price is currently up 13.79% so far this month.
During the month of April, NervGen Pharma Corp.’s stock price has reached a high of $4.670 and a low of $3.775.
Over the last year, NervGen Pharma Corp. has hit prices as high as $6.300 and as low as $1.500. Year to date, NervGen Pharma Corp.’s stock is up 2144900%.
Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions
What Caused NervGen Pharma Corp. Stock’s Price to Rise?
Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?
One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of April 14, 2026,, no analysts have changed their rating of NervGen Pharma Corp.’s stock over the last month.
Additionally, you'll want to evaluate NervGen Pharma Corp.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on NervGen Pharma Corp.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.
Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.
Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about NervGen Pharma Corp. (NGEN) by visiting AAII Stock Evaluator.
Relative Price Strength of NervGen Pharma Corp.
Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.
For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.
As of April 14, 2026, NervGen Pharma Corp. has a weighted four-quarter relative price strength of 8.08%, which translates to a Momentum Score of 74 and is considered to be Strong.
Want to learn more about how NervGen Pharma Corp. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.
NervGen Pharma Corp. Stock Price: Bottom Line
As of April 15, 2026, NervGen Pharma Corp.’s stock price is $4.290, which is up 2.39% from its previous closing price.
AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like NervGen Pharma Corp. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.
Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.
Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate NervGen Pharma Corp. before investing.
In this article, we go over a few key elements for understanding NervGen Pharma Corp.’s stock price such as:
- NervGen Pharma Corp.’s current stock price and volume
- Why NervGen Pharma Corp.’s stock price changed recently
- Upgrades and downgrades for NGEN from analysts
- NGEN’s stock price momentum as measured by its relative strength
About NervGen Pharma Corp. (NGEN)
Before we jump into NervGen Pharma Corp.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company’s lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer’s disease; and NVG-300, which is in a preclinical model of ischemic stroke and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.
Want to learn more about NervGen Pharma Corp.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about NervGen Pharma Corp..
NervGen Pharma Corp.’s Stock Price as of Market Close
As of April 15, 2026, 3:16 PM, CST, NervGen Pharma Corp.’s stock price was $4.290.
NervGen Pharma Corp. is up 2.39% from its previous closing price of $4.190.
During the last market session, NervGen Pharma Corp.’s stock traded between $4.160 and $4.350. Currently, there are approximately 53.61 million shares outstanding for NervGen Pharma Corp..
NervGen Pharma Corp.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.
NervGen Pharma Corp. Stock Price History
NervGen Pharma Corp.’s (NGEN) price is currently up 13.79% so far this month.
During the month of April, NervGen Pharma Corp.’s stock price has reached a high of $4.670 and a low of $3.775.
Over the last year, NervGen Pharma Corp. has hit prices as high as $6.300 and as low as $1.500. Year to date, NervGen Pharma Corp.’s stock is up 2144900%.
Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions
What Caused NervGen Pharma Corp. Stock’s Price to Rise?
Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?
One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of April 14, 2026,, no analysts have changed their rating of NervGen Pharma Corp.’s stock over the last month.
Additionally, you'll want to evaluate NervGen Pharma Corp.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on NervGen Pharma Corp.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.
Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.
Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about NervGen Pharma Corp. (NGEN) by visiting AAII Stock Evaluator.
Relative Price Strength of NervGen Pharma Corp.
Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.
For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.
As of April 14, 2026, NervGen Pharma Corp. has a weighted four-quarter relative price strength of 8.08%, which translates to a Momentum Score of 74 and is considered to be Strong.
Want to learn more about how NervGen Pharma Corp. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.
NervGen Pharma Corp. Stock Price: Bottom Line
As of April 15, 2026, NervGen Pharma Corp.’s stock price is $4.290, which is up 2.39% from its previous closing price.
AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like NervGen Pharma Corp. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.
Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.
Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate NervGen Pharma Corp. before investing.
In this article, we go over a few key elements for understanding NervGen Pharma Corp.’s stock price such as:
- NervGen Pharma Corp.’s current stock price and volume
- Why NervGen Pharma Corp.’s stock price changed recently
- Upgrades and downgrades for NGEN from analysts
- NGEN’s stock price momentum as measured by its relative strength
About NervGen Pharma Corp. (NGEN)
Before we jump into NervGen Pharma Corp.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company’s lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer’s disease; and NVG-300, which is in a preclinical model of ischemic stroke and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.
Want to learn more about NervGen Pharma Corp.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about NervGen Pharma Corp..
NervGen Pharma Corp.’s Stock Price as of Market Close
As of April 15, 2026, 3:16 PM, CST, NervGen Pharma Corp.’s stock price was $4.290.
NervGen Pharma Corp. is up 2.39% from its previous closing price of $4.190.
During the last market session, NervGen Pharma Corp.’s stock traded between $4.160 and $4.350. Currently, there are approximately 53.61 million shares outstanding for NervGen Pharma Corp..
NervGen Pharma Corp.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.
NervGen Pharma Corp. Stock Price History
NervGen Pharma Corp.’s (NGEN) price is currently up 13.79% so far this month.
During the month of April, NervGen Pharma Corp.’s stock price has reached a high of $4.670 and a low of $3.775.
Over the last year, NervGen Pharma Corp. has hit prices as high as $6.300 and as low as $1.500. Year to date, NervGen Pharma Corp.’s stock is up 2144900%.
Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions
What Caused NervGen Pharma Corp. Stock’s Price to Rise?
Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?
One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of April 14, 2026,, no analysts have changed their rating of NervGen Pharma Corp.’s stock over the last month.
Additionally, you'll want to evaluate NervGen Pharma Corp.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on NervGen Pharma Corp.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.
Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.
Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about NervGen Pharma Corp. (NGEN) by visiting AAII Stock Evaluator.
Relative Price Strength of NervGen Pharma Corp.
Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.
For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.
As of April 14, 2026, NervGen Pharma Corp. has a weighted four-quarter relative price strength of 8.08%, which translates to a Momentum Score of 74 and is considered to be Strong.
Want to learn more about how NervGen Pharma Corp. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.
NervGen Pharma Corp. Stock Price: Bottom Line
As of April 15, 2026, NervGen Pharma Corp.’s stock price is $4.290, which is up 2.39% from its previous closing price.
AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like NervGen Pharma Corp. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.
Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.
Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate NervGen Pharma Corp. before investing.
In this article, we go over a few key elements for understanding NervGen Pharma Corp.’s stock price such as:
- NervGen Pharma Corp.’s current stock price and volume
- Why NervGen Pharma Corp.’s stock price changed recently
- Upgrades and downgrades for NGEN from analysts
- NGEN’s stock price momentum as measured by its relative strength
About NervGen Pharma Corp. (NGEN)
Before we jump into NervGen Pharma Corp.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company’s lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer’s disease; and NVG-300, which is in a preclinical model of ischemic stroke and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.
Want to learn more about NervGen Pharma Corp.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about NervGen Pharma Corp..
NervGen Pharma Corp.’s Stock Price as of Market Close
As of April 15, 2026, 3:16 PM, CST, NervGen Pharma Corp.’s stock price was $4.290.
NervGen Pharma Corp. is up 2.39% from its previous closing price of $4.190.
During the last market session, NervGen Pharma Corp.’s stock traded between $4.160 and $4.350. Currently, there are approximately 53.61 million shares outstanding for NervGen Pharma Corp..
NervGen Pharma Corp.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.
NervGen Pharma Corp. Stock Price History
NervGen Pharma Corp.’s (NGEN) price is currently up 13.79% so far this month.
During the month of April, NervGen Pharma Corp.’s stock price has reached a high of $4.670 and a low of $3.775.
Over the last year, NervGen Pharma Corp. has hit prices as high as $6.300 and as low as $1.500. Year to date, NervGen Pharma Corp.’s stock is up 2144900%.
Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions
What Caused NervGen Pharma Corp. Stock’s Price to Rise?
Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?
One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of April 14, 2026,, no analysts have changed their rating of NervGen Pharma Corp.’s stock over the last month.
Additionally, you'll want to evaluate NervGen Pharma Corp.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on NervGen Pharma Corp.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.
Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.
Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about NervGen Pharma Corp. (NGEN) by visiting AAII Stock Evaluator.
Relative Price Strength of NervGen Pharma Corp.
Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.
For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.
As of April 14, 2026, NervGen Pharma Corp. has a weighted four-quarter relative price strength of 8.08%, which translates to a Momentum Score of 74 and is considered to be Strong.
Want to learn more about how NervGen Pharma Corp. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.
NervGen Pharma Corp. Stock Price: Bottom Line
As of April 15, 2026, NervGen Pharma Corp.’s stock price is $4.290, which is up 2.39% from its previous closing price.
AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like NervGen Pharma Corp. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.
Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.
Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate NervGen Pharma Corp. before investing.
In this article, we go over a few key elements for understanding NervGen Pharma Corp.’s stock price such as:
- NervGen Pharma Corp.’s current stock price and volume
- Why NervGen Pharma Corp.’s stock price changed recently
- Upgrades and downgrades for NGEN from analysts
- NGEN’s stock price momentum as measured by its relative strength
About NervGen Pharma Corp. (NGEN)
Before we jump into NervGen Pharma Corp.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company’s lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer’s disease; and NVG-300, which is in a preclinical model of ischemic stroke and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.
Want to learn more about NervGen Pharma Corp.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about NervGen Pharma Corp..
NervGen Pharma Corp.’s Stock Price as of Market Close
As of April 15, 2026, 3:16 PM, CST, NervGen Pharma Corp.’s stock price was $4.290.
NervGen Pharma Corp. is up 2.39% from its previous closing price of $4.190.
During the last market session, NervGen Pharma Corp.’s stock traded between $4.160 and $4.350. Currently, there are approximately 53.61 million shares outstanding for NervGen Pharma Corp..
NervGen Pharma Corp.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.
NervGen Pharma Corp. Stock Price History
NervGen Pharma Corp.’s (NGEN) price is currently up 13.79% so far this month.
During the month of April, NervGen Pharma Corp.’s stock price has reached a high of $4.670 and a low of $3.775.
Over the last year, NervGen Pharma Corp. has hit prices as high as $6.300 and as low as $1.500. Year to date, NervGen Pharma Corp.’s stock is up 2144900%.
Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions
What Caused NervGen Pharma Corp. Stock’s Price to Rise?
Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?
One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of April 14, 2026,, no analysts have changed their rating of NervGen Pharma Corp.’s stock over the last month.
Additionally, you'll want to evaluate NervGen Pharma Corp.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on NervGen Pharma Corp.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.
Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.
Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about NervGen Pharma Corp. (NGEN) by visiting AAII Stock Evaluator.
Relative Price Strength of NervGen Pharma Corp.
Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.
For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.
As of April 14, 2026, NervGen Pharma Corp. has a weighted four-quarter relative price strength of 8.08%, which translates to a Momentum Score of 74 and is considered to be Strong.
Want to learn more about how NervGen Pharma Corp. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.
NervGen Pharma Corp. Stock Price: Bottom Line
As of April 15, 2026, NervGen Pharma Corp.’s stock price is $4.290, which is up 2.39% from its previous closing price.
AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like NervGen Pharma Corp. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.
Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.
Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate NervGen Pharma Corp. before investing.
In this article, we go over a few key elements for understanding NervGen Pharma Corp.’s stock price such as:
- NervGen Pharma Corp.’s current stock price and volume
- Why NervGen Pharma Corp.’s stock price changed recently
- Upgrades and downgrades for NGEN from analysts
- NGEN’s stock price momentum as measured by its relative strength
About NervGen Pharma Corp. (NGEN)
Before we jump into NervGen Pharma Corp.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company’s lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer’s disease; and NVG-300, which is in a preclinical model of ischemic stroke and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.
Want to learn more about NervGen Pharma Corp.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about NervGen Pharma Corp..
NervGen Pharma Corp.’s Stock Price as of Market Close
As of April 15, 2026, 3:16 PM, CST, NervGen Pharma Corp.’s stock price was $4.290.
NervGen Pharma Corp. is up 2.39% from its previous closing price of $4.190.
During the last market session, NervGen Pharma Corp.’s stock traded between $4.160 and $4.350. Currently, there are approximately 53.61 million shares outstanding for NervGen Pharma Corp..
NervGen Pharma Corp.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.
NervGen Pharma Corp. Stock Price History
NervGen Pharma Corp.’s (NGEN) price is currently up 13.79% so far this month.
During the month of April, NervGen Pharma Corp.’s stock price has reached a high of $4.670 and a low of $3.775.
Over the last year, NervGen Pharma Corp. has hit prices as high as $6.300 and as low as $1.500. Year to date, NervGen Pharma Corp.’s stock is up 2144900%.
Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions
What Caused NervGen Pharma Corp. Stock’s Price to Rise?
Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?
One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of April 14, 2026,, no analysts have changed their rating of NervGen Pharma Corp.’s stock over the last month.
Additionally, you'll want to evaluate NervGen Pharma Corp.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on NervGen Pharma Corp.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.
Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.
Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about NervGen Pharma Corp. (NGEN) by visiting AAII Stock Evaluator.
Relative Price Strength of NervGen Pharma Corp.
Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.
For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.
As of April 14, 2026, NervGen Pharma Corp. has a weighted four-quarter relative price strength of 8.08%, which translates to a Momentum Score of 74 and is considered to be Strong.
Want to learn more about how NervGen Pharma Corp. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.
NervGen Pharma Corp. Stock Price: Bottom Line
As of April 15, 2026, NervGen Pharma Corp.’s stock price is $4.290, which is up 2.39% from its previous closing price.
AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like NervGen Pharma Corp. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.
Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.
Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate NervGen Pharma Corp. before investing.
In this article, we go over a few key elements for understanding NervGen Pharma Corp.’s stock price such as:
- NervGen Pharma Corp.’s current stock price and volume
- Why NervGen Pharma Corp.’s stock price changed recently
- Upgrades and downgrades for NGEN from analysts
- NGEN’s stock price momentum as measured by its relative strength
About NervGen Pharma Corp. (NGEN)
Before we jump into NervGen Pharma Corp.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company’s lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer’s disease; and NVG-300, which is in a preclinical model of ischemic stroke and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.
Want to learn more about NervGen Pharma Corp.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about NervGen Pharma Corp..
NervGen Pharma Corp.’s Stock Price as of Market Close
As of April 15, 2026, 3:16 PM, CST, NervGen Pharma Corp.’s stock price was $4.290.
NervGen Pharma Corp. is up 2.39% from its previous closing price of $4.190.
During the last market session, NervGen Pharma Corp.’s stock traded between $4.160 and $4.350. Currently, there are approximately 53.61 million shares outstanding for NervGen Pharma Corp..
NervGen Pharma Corp.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.
NervGen Pharma Corp. Stock Price History
NervGen Pharma Corp.’s (NGEN) price is currently up 13.79% so far this month.
During the month of April, NervGen Pharma Corp.’s stock price has reached a high of $4.670 and a low of $3.775.
Over the last year, NervGen Pharma Corp. has hit prices as high as $6.300 and as low as $1.500. Year to date, NervGen Pharma Corp.’s stock is up 2144900%.
Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions
What Caused NervGen Pharma Corp. Stock’s Price to Rise?
Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?
One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of April 14, 2026,, no analysts have changed their rating of NervGen Pharma Corp.’s stock over the last month.
Additionally, you'll want to evaluate NervGen Pharma Corp.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on NervGen Pharma Corp.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.
Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.
Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about NervGen Pharma Corp. (NGEN) by visiting AAII Stock Evaluator.
Relative Price Strength of NervGen Pharma Corp.
Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.
For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.
As of April 14, 2026, NervGen Pharma Corp. has a weighted four-quarter relative price strength of 8.08%, which translates to a Momentum Score of 74 and is considered to be Strong.
Want to learn more about how NervGen Pharma Corp. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.
NervGen Pharma Corp. Stock Price: Bottom Line
As of April 15, 2026, NervGen Pharma Corp.’s stock price is $4.290, which is up 2.39% from its previous closing price.
AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like NervGen Pharma Corp. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.
Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.
Included With AAII Platinum
Yield Screen: 8.7% Compared to S&P 500
at only 6.9%
Since Inception. Data as of 12/31/2024.
769.3% Stock Superstars Portfolio Total Return Since Inception
U.S. Index ETF (IYY)
SSR Group 3 O'Shaughnessy portfolio has a 411.2% gain since inception performance compared to IYY at only 119.1%% Performance as of 11/29/24.
FREE REPORT
BECOME A MEMBER FOR ONLY $2
Get access to powerful investment discovery tools and a wealth of investment education to help you achieve your financial goals.